What question did this study set out to answer?

This research aims to characterize the immune landscape of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy.

December 8, 2025Blood

Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy

View Full Paper

Ask AI

Bookmark

Authors

SSSelma SorriUniversity of Helsinki KKKerttu KalanderUniversity of Helsinki SLSirpa LeppäUniversity of Helsinki

Discussion

Member takes

Implication

Flow cytometry reveals distinct immune profiles and tumor microenvironment dynamics in B-cell lymphoma patients after CAR-T therapy, suggesting pathways for efficacy improvement.

Key Points

This research aims to characterize the immune landscape of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy.
Sequential blood samples were collected from patients to monitor immune responses.
Flow cytometry was performed to analyze immune cell populations.
Single cell RNA-sequencing was conducted on selected samples to obtain detailed immune profiles.
Distinct immune profiles were observed in patients at different time points after CAR-T therapy.
A correlation was found between low monocyte percentage and patient response outcomes.
Higher proportions of CD4 T effector memory cells were noted in patients treated with tisacel compared to axicel.

Cite This Study

Sorri et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3f9 https://doi.org/10.1182/blood-2025-2342

View Full Paper

Ask AI

Bookmark

Implication

Flow cytometry reveals distinct immune profiles and tumor microenvironment dynamics in B-cell lymphoma patients after CAR-T therapy, suggesting pathways for efficacy improvement.

Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider